Canada Gazette, Part I, Volume 153, Number 13: GOVERNMENT NOTICES

March 30, 2019

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Ministerial Condition No. 19882

Ministerial condition

(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)

Whereas the Minister of the Environment and the Minister of Health (the ministers) have assessed information pertaining to the substance iron(1+), chloro[dimethyl 9,9dihydroxy-3-methyl-2,4-di(2-pyridinyl-κN)-7-[(2-pyridinylκN)methyl]- 3,7-diazabicyclo[3.3.1]nonane-1,5-dicarboxylateκN3, κN7]-, chloride (1:1), Chemical Abstracts Service Registry No. 478945-46-9;

And whereas the ministers suspect that the substance is toxic or capable of becoming toxic within the meaning of section 64 of the Canadian Environmental Protection Act, 1999 (the Act),

The Minister of the Environment, pursuant to paragraph 84(1)(a) of the  Act, hereby permits the manufacture or import of the substance in accordance with the conditions of the following annex.

Nancy Hamzawi
Assistant Deputy Minister
Science and Technology Branch

On behalf of the Minister of the Environment

ANNEX

Conditions

(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)

1. The following definitions apply in these ministerial conditions:

2. The notifier may manufacture or import the substance in accordance with the present ministerial conditions.

Restrictions

3. The substance shall only be used to manufacture a paint or a coating and the following conditions must be met:

4. The notifier shall transfer the physical possession or control of the substance only to a person who will use it in accordance with item 3.

5. At least 120 days prior to beginning manufacturing the substance in Canada, the notifier shall inform the Minister of the Environment, in writing, and provide the following information:

Record-keeping requirements

6. (1) The notifier shall maintain electronic or paper records, with any documentation supporting the validity of the information contained in these records, indicating

(2) The notifier shall maintain electronic or paper records mentioned in subsection (1) at their principal place of business in Canada, or at the principal place of business in Canada of their representative, for a period of at least five years after they are made.

Other requirements

7. The notifier shall inform any person to whom they transfer the physical possession or control of the substance, in writing, of the terms of the present ministerial conditions. The notifier shall obtain, prior to the first transfer of the substance, written confirmation from this person that they were informed of the terms of the present ministerial conditions. This written confirmation shall be maintained at the principal place of business in Canada of the notifier or of their representative in Canada for a period of at least five years from the day it was received.

Coming into force

8. The present ministerial conditions come into force on March 13, 2019.

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Notice of waiver of information requirements for living organisms (subsection 106(9) of the Canadian Environmental Protection Act, 1999)

Whereas any person who proposes to import or manufacture a living organism that is not on the Domestic Substances List must provide to the Minister of the Environment the information required under subsection 106(1) of the Canadian Environmental Protection Act, 1999;

Whereas a person may, pursuant to subsection 106(8) of the Canadian Environmental Protection Act, 1999, request any of the requirements to provide information under subsection 106(1) of the Canadian Environmental Protection Act, 1999 to be waived;

Whereas a waiver may be granted by the Minister of the Environment under subsection 106(8) of the Canadian Environmental Protection Act, 1999 if

Therefore, notice is hereby given, pursuant to subsection 106(9) of the Canadian Environmental Protection Act, 1999, that the Minister of the Environment waived some requirements to provide information in accordance with the following annex pursuant to subsection 106(8) of that Act.

Nicole Davidson
Acting Executive Director
Program Development and Engagement Division

On behalf of the Minister of the Environment

ANNEX

Notice of waiver of information requirements

(Subsection 106(9) of the Canadian Environmental Protection Act, 1999)

Person to whom a waiver was granted

Information concerning a living organism in relation to which a waiver was granted

AquaBounty Technologies Inc.

Data from a test to determine the ecological effects of the living organism (pathogenicity, toxicity or invasiveness)

GlaxoSmithKline Inc.

Data from a test to determine the effects of the living organism on aquatic plant, invertebrate, and vertebrate species likely to be exposed

Data from a test to determine the effects of the living organism on terrestrial plant and invertebrate species likely to be exposed

Data from tests of antibiotic susceptibility

Iovance Biotherapeutics, Inc.

Data from a test to determine the effects of the living organism on aquatic plant, invertebrate, and vertebrate species likely to be exposed

Data from a test to determine the effects of the living organism on terrestrial plant and invertebrate species likely to be exposed

Data from tests of antibiotic susceptibility

EXPLANATORY NOTE

The decision to grant a waiver is made on a case-by-case basis by Environment Canada in consultation with Health Canada. Every year an average of 500 regulatory declarations are submitted for chemicals, polymers and living organisms under subsections 81(1), (3) and (4) and 106(1), (3) and (4) of the Canadian Environmental Protection Act, 1999 and around 100 waivers are granted yearly for chemicals, polymers and living organisms under subsections 81(8) and 106(8) of the Canadian Environmental Protection Act, 1999.

For more information, please see the waivers web page on the New Substances website.

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Notice of waiver of information requirements for substances (subsection 81(9) of the Canadian Environmental Protection Act, 1999)

Whereas any person who proposes to import or manufacture a substance that is not on the Domestic Substances List must provide to the Minister of the Environment the information required under subsection 81(1) of the Canadian Environmental Protection Act, 1999;

Whereas a person may, pursuant to subsection 81(8) of the Canadian Environmental Protection Act, 1999, request any of the requirements to provide information under subsection 81(1) of the Canadian Environmental Protection Act, 1999 to be waived; and

Whereas a waiver may be granted by the Minister of the Environment under subsection 81(8) of the Canadian Environmental Protection Act, 1999 if

Therefore, notice is hereby given, pursuant to subsection 81(9) of the Canadian Environmental Protection Act, 1999, that the Minister of the Environment waived some requirements to provide information pursuant to subsection 81(8) of that Act and in accordance with the following annex.

Nicole Davidson
Acting Executive Director
Program Development and Engagement Division

On behalf of the Minister of the Environment

ANNEX

Notice of waiver of information requirements

(Subsection 81(9) of the Canadian Environmental Protection Act, 1999)

Person to whom a waiver was granted

Information concerning a substance in relation to which a waiver was granted

Table 1 Notes

Table 1 Note 1

The number in brackets indicates the number of times that the information requirement in the second column was waived for the company.

Return to table 1 note 1 referrer

BASF Canada Inc.

Data in respect of octanol/water partition coefficient

Data in respect of hydrolysis rate as a function of pH

Dow Chemical Canada ULC

Data from an in vivo mammalian test for chromosomal aberrations or gene mutations

H.B. Fuller Canada

Data in respect of octanol/water partition coefficient (2) table 1 note 1

Data in respect of hydrolysis rate as a function of pH (2)

INEOS Oligomers USA LLC

Data in respect of hydrolysis rate as a function of pH

Rohm and Haas Canada LP

Data in respect of octanol/water partition coefficient

Showa Denko K.K.

Data in respect of water solubility

Data from an acute mammalian toxicity test (oral, dermal or inhalation)

Data from an in vitro mutagenicity test for chromosomal aberrations in mammalian cells

Solenis Canada ULC

Data in respect of octanol/water partition coefficient

Data in respect of hydrolysis rate as a function of pH

W.R. Grace & Co.-Conn.

Data in respect of vapour pressure

Data in respect of octanol/water partition coefficient

Data in respect of ready biodegradation

Data in respect of adsorption-desorption

EXPLANATORY NOTE

The decision to grant a waiver is made on a case-by-case basis by Environment Canada in consultation with Health Canada. Every year an average of 500 regulatory declarations are submitted for chemicals, polymers and living organisms under subsections 81(1), (3) and (4) and 106(1), (3) and (4) of the Canadian Environmental Protection Act, 1999 and around 100 waivers are granted yearly for chemicals, polymers and living organisms under subsections 81(8) and 106(8) of the Canadian Environmental Protection Act, 1999.

For more information, please see the waivers web page on the New Substances website.

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Notice with respect to the availability of an equivalency agreement

Pursuant to subsection 10(4) of the Canadian Environmental Protection Act, 1999, notice is hereby given that the Minister of the Environment makes available, before it is entered into, An Agreement on the Equivalency of Federal and British Columbia Regulations Respecting the Release of Methane from the Upstream Oil and Gas Sector in British Columbia, 2020.

The proposed agreement is available as of March 30, 2019, on the Department of the Environment’s Environmental Registry.

Any person may, within 60 days after the publication of this notice, file with the Minister comments or a notice of objection. All such comments and notices must cite the present notice and its date of publication in the Canada Gazette, Part I, and be sent to the following contact person.

Contact

Cam Carruthers
Executive Director
Oil, Gas and Alternative Energy Division
Department of the Environment
351 Saint-Joseph Boulevard
Gatineau, Quebec
K1A 0H3
Email: ec.methane-methane.ec@canada.ca

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Notice with respect to the availability of an equivalency agreement

Pursuant to subsection 10(4) of the Canadian Environmental Protection Act, 1999, notice is hereby given that the Minister of the Environment makes available, before it is entered into, the Agreement on the equivalency of federal and Nova Scotia regulations for the control of greenhouse gas emissions from electricity producers in Nova Scotia.

The proposed agreement is available as of March 30, 2019, on the Department of the Environment’s Environmental Registry.

Any person may, within 60 days after the publication of this notice, file with the Minister comments or a notice of objection. All such comments and notices must cite the present notice and its date of publication in the Canada Gazette, Part I, and be sent to the following contact person.

Contact

Magda Little
Director
Electricity and Combustion Division
Department of the Environment
351 Saint-Joseph Boulevard
Gatineau, Quebec
K1A 0H3
Email: ec.electricite-electricity.ec@canada.ca

DEPARTMENT OF THE ENVIRONMENT

Significant New Activity Notice No. 19794

Significant New Activity Notice

(Section 85 of the Canadian Environmental Protection Act, 1999)

Whereas the Minister of the Environment and the Minister of Health have assessed information in their possession in respect of the substance 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2- propenoate and 3-[3,3,3-trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl]propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4, under section 83 of the Canadian Environmental Protection Act, 1999;

Whereas the substance is not specified on the Domestic Substances List;

And whereas the Ministers suspect that a significant new activity in relation to the substance may result in the substance becoming toxic within the meaning of section 64 of the Act,

Therefore, the Minister of the Environment indicates, pursuant to section 85 of the Canadian Environmental Protection Act, 1999, that subsection 81(4) of that Act applies with respect to the substance in accordance with the Annex.

March 11, 2019

The Honourable Catherine McKenna
Minister of the Environment

ANNEX

Information requirements

(Section 85 of the Canadian Environmental Protection Act, 1999)

1. The following definition applies in this notice:

2. In relation to the substance, a significant new activity is

3. Despite section 2, a use of the substance is not a significant new activity if the substance is used

4. For each proposed significant new activity, the following information must be provided to the Minister of the Environment at least 90 days before the day on which the activity begins:

5. The information provided under section 4 will be assessed within 90 days after the day on which it is received by the Minister of the Environment.

Transitional provisions

6. Despite section 2, in the period between the date of publication of the present notice and March 30, 2020, a significant new activity is the use of the substance in a quantity greater than or equal to 1 000 kg in a calendar year in the manufacture or distribution for sale of the following products in which the substance is present in a concentration greater than or equal to 1% by weight:

7. For greater certainty, in respect of calendar year 2020, the quantity of substance that is used before March 30 of that calendar year is not considered for the purposes of section 2.

EXPLANATORY NOTE

(This explanatory note is not part of the Significant New Activity Notice.)

Description

This Significant New Activity (SNAc) Notice is a legal instrument adopted by the Minister of the Environment pursuant to section 85 of the Canadian Environmental Protection Act, 1999 (the Act) to apply the SNAc provisions of that Act to 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2-propenoate and 3-[3,3,3- trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl]propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4. The Notice is now in force. It is therefore mandatory to meet all the requirements of the Notice should a person intend to use the substance for a significant new activity as defined in the Notice.

A SNAc Notice does not constitute an endorsement from the Department of the Environment or the Government of Canada of the substance to which it relates, or an exemption from any other laws or regulations that are in force in Canada and that may apply to this substance or activities involving the substance.

Applicability of the Significant New Activity Notice

The Notice requires that any person (individual or corporation) engaging in a SNAc in relation to 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2- propenoate and 3-[3,3,3-trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl]propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4, submit a Significant New Activity Notification (SNAN) containing all of the information prescribed in the Notice at least 90 days prior to using the substance for the SNAc.

In order to address the human toxicity concerns, the Notice requires notification in relation to the use of the substance in the manufacture of consumer products or cosmetics intended for applications that generate airborne particles of less than or equal to 10 µm when the concentration of the substance is greater or equal to 1% by weight. The Notice also requires notification in relation to the distribution for sale of the substance in these finished products. For example, notification is required if a person plans to manufacture or distribute an aerosol cosmetic product containing the substance that generates respirable airborne particles of less than or equal to 10 µm, and the concentration of the substance is greater or equal to 1% by weight.

The Notice targets any use of the substance in consumer products to which the Canada Consumer Product Safety Act (CCPSA) applies, or in a cosmetic as defined in the Food and Drugs Act (FDA). A SNAN is required 90 days before the use of the substance in a SNAc.

Activities not subject to the Notice

The following activities are not significant new activities:

Uses of the substance that are regulated under the acts of Parliament listed in Schedule 2 of the Act, including the Pest Control Products Act, the Fertilizers Act and the Feeds Act, are excluded from the Notice. The Notice also does not apply to transient reaction intermediates, impurities, contaminants, partially unreacted materials or, in some circumstances, to items such as, but not limited to, wastes, mixtures, or manufactured items. However, it should be noted that individual components of a mixture may be subject to notification under the provisions of the Act. See subsection 81(6) and section 3 of the Act, and section 3 of the Guidelines for the Notification and Testing of New Substances: Chemicals and Polymers for additional information.

Activities involving the use of the substance as a research and development substance or a site-limited intermediate or an export-only product are excluded from the Notice. The terms “research and development substance” and “site-limited intermediate substance” are defined in subsection 1(1) of the New Substances Notification Regulations (Chemicals and Polymers).

Information to be submitted

The Notice sets out the information that must be provided to the Minister 90 days before the day on which the substance 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2-propenoate and 3-[3,3,3- trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl]propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4, is used for a SNAc. The Department of the Environment and the Department of Health will use the information submitted in the SNAN to conduct risk assessments within 90 days after the complete information is received.

The earlier assessment of the substance identified potential concerns associated with uses of the substance in consumer spray applications that generate respirable airborne particles of less than or equal to 10 µm. This acrylate silicone copolymer with high molecular weight and water-insoluble components can potentially cause pulmonary complications if inhaled. The SNAc Notice is issued to gather toxicity information in the event that the substance is used in a consumer spray application that generates airborne particles of less than or equal to 10 µm to ensure that the substance will undergo further assessment before SNAcs are undertaken.

The information requirements in the Notice relate to general information in respect of the substance, details surrounding its use, exposure information, and toxicity to human health. Some of the information requirements reference the New Substances Notification Regulations (Chemicals and Polymers).

Additional guidance on preparing a SNAN can be found in section 1.3 of the Guidelines for the Notification and Testing of New Substances: Chemicals and Polymers.

Transitional provision

A transitional provision is included in the Notice to facilitate compliance by persons who may already have imported or manufactured up to 1 000 kg of the substance and started activities with it in concentrations that are greater than or equal to 1% by weight in the product matrix. The Notice comes into force immediately. However, if the substance is used to manufacture or distribute for sale consumer products to which the CCPSA applies or cosmetics as defined in the FDA that release or spray the substance in airborne particles of less than or equal to 10 µm in size, a threshold of more than or equal to 1 000 kg per calendar year applies and a concentration equal to or greater than 1% by weight applies for the period between the publication of the Notice and March 30, 2020. On March 31, 2020, the threshold will be lowered to 0 kg per calendar year when the substance is used to manufacture consumer or cosmetic products that release or spray the substance in airborne particles of less than 10 µm in size, and the concentration will remain greater than or equal to 1% by weight. On March 31, 2020, the threshold will be lowered to 10 kg per calendar year when consumer or cosmetic products that release or spray the substance in airborne particles of less than or equal to 10 µm in size are intended for distribution for sale, and the concentration will remain greater than or equal to 1% by weight.

Compliance

When assessing whether or not a substance is subject to SNAc provisions, a person is expected to make use of information in their possession or to which they may reasonably have access. This means information in any of the notifier’s offices worldwide or other locations where the notifier can reasonably have access to the information. For example, manufacturers are expected to have access to their formulations, while importers or users of a substance, mixture, or product are expected to have access to import records, usage information and the relevant safety data sheets (SDSs).

Although an SDS is an important source of information on the composition of a product, it should be noted that the goal of the SDS is to protect the health of workers in the workplace from specific hazards of chemical products. Therefore, an SDS may not list all product ingredients that may be subject to a SNAc notice due to human health or environmental concerns. Any person requiring more detailed information on product composition is encouraged to contact their supplier.

If any information becomes available that reasonably supports the conclusion that 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2-propenoate and 3-[3,3,3-trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl] propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4, is toxic or capable of becoming toxic, the person who is in possession of or that has knowledge of the information and is involved in activities with the substance is obligated, under section 70 of the Act, to provide that information to the Minister without delay.

A company can submit a SNAN on behalf of its clients. For example, in cases where a person takes possession or control of a substance from another person, they may not be required to submit a SNAN, under certain conditions, if their activities were covered by an original SNAN submitted by the person from whom they obtained the substance. The Substances Management Advisory Note “Clarification in relation to the submission of Significant New Activity Notifications in application of the Canadian Environmental Protection Act, 1999” provides more detail on this subject.

Under section 86 of the Act, any person who transfers the physical possession or control of a substance subject to a SNAc notice must notify all persons to whom the physical possession or control is transferred of the obligation to comply with the notice, including the obligation to notify the Minister of any SNAc and to provide all the required information outlined above.

A pre-notification consultation (PNC) is recommended for notifiers who wish to consult with the program during the planning or preparation of their SNAN to discuss any questions or concerns they have about the prescribed information and test plans.

Where a person has questions concerning their obligations to comply with a notice, believes they may be out of compliance, or would like to request a PNC, they are encouraged to discuss their particular circumstances with the program by contacting the Substances Management Information Line (eccc.substances.eccc@canada.ca [email], 1-800‑567‑1999 [toll-free in Canada], and 819‑938‑3232 [outside of Canada]).

The Act is enforced in accordance with the publicly available Compliance and Enforcement Policy for the Canadian Environmental Protection Act, 1999. In instances of non-compliance, consideration is given to factors such as the nature of the alleged violation, potential harm, intent, and history of compliance.

DEPARTMENT OF HEALTH

CANNABIS ACT

Increase of fees

The Cannabis Fees Order (SOR/2018-198) was published in the Canada Gazette, Part II, on October 17, 2018, and came into force on the same date.

Section 2 of the Order provides that “the fees set out in sections 3 to 5 are to be adjusted in each fiscal year on April 1 by the percentage change over 12 months in the April All-items Consumer Price Index for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year and rounded to the next highest dollar.”

Notice is hereby given that the following fees will be adjusted effective April 1, 2019, by the 2018 Consumer Price Index of 2.2%.

Fee Description

Current Fee

Adjusted Fee Effective
April 1, 2019

Screening of a licence application

  • Licence for micro-cultivation

$1,638

$1,675

  • Licence for standard cultivation

$3,277

$3,350

  • Licence for a nursery

$1,638

$1,675

  • Licence for micro-processing

$1,638

$1,675

  • Licence for standard processing

$3,277

$3,350

  • Licence for sale for medical purposes

$3,277

$3,350

Application for security clearance

$1,654

$1,691

Application for import or export permit

$610

$624

John Clare
Acting Director General
Strategic Policy Directorate
Controlled Substances and Cannabis Branch

DEPARTMENT OF HEALTH

DEPARTMENT OF HEALTH ACT

Notice of annual increase of Health Canada’s Drug Master Files and Certificate of a Pharmaceutical Product fees

Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, hereby updates the fees that are payable for the provision of Drug Master Files and Certificate of a Pharmaceutical Product services by 2%, beginning April 1, 2019.

The current fees and the fees updated as of April 1, 2019, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or hc.cro- brc.sc@canada.ca (email).

Services

Fee as of April 1, 2018

Fee as of April 1, 2019

Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product)

$88

$90

New Master Files — file registration

$1,224

$1,248

Drug Master Files — letter of access

$173

$176

Drug Master Files — update

$530

$541

DEPARTMENT OF HEALTH

FINANCIAL ADMINISTRATION ACT

Notice of annual increase of fees pursuant to the Fees in Respect of Drugs and Medical Devices Regulations

Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the 2011 Fees in Respect of Drugs and Medical Devices Regulations, every fee outlined by the Regulations is to be increased annually by 2%, rounded up to the nearest dollar.

The current fees and the fees updated as of April 1, 2019, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or hc.cro-brc.sc@canada.ca (email).

Fee Category

Section in Fees in Respect of Drugs and Medical Devices Regulations

Fee as of April 1, 2018

Fee as of April 1, 2019

PART 2 — DRUGS

Fees For Examination Services — Schedule 1

New active substance

6

$348,606

$355,579

Clinical or non-clinical data and chemistry and manufacturing data

6

$176,569

$180,101

Clinical or non-clinical data only

6

$82,410

$84,059

Comparative studies

6

$49,811

$50,808

Chemistry and manufacturing data only

6

$23,551

$24,023

Published data only

6

$19,530

$19,921

Switch from prescription to non-prescription status

6

$47,421

$48,370

Labelling only

6

$3,174

$3,238

Administrative submission

6

$331

$338

Disinfectants

6

$4,392

$4,480

Drug identification number application — labelling standards

6

$1,761

$1,797

Remission

Remission processing fee

11(1)(a)9)iii)

$578

$590

Establishment Licence Fees

Fabrication of Drugs — Schedule 2

Basic fee

19(1), 27, 28(1)(a), 28(2)(a)

$17,751

$18,107

Each additional category

19(1)(a)

$4,449

$4,538

Dosage form classes:

   

2 classes

19(1)(b)

$8,883

$9,061

3 classes

19(1)(b)

$17,751

$18,107

4 classes

19(1)(b)

$22,198

$22,642

5 classes

19(1)(b)

$26,629

$27,162

6 classes

19(1)(b)

$31,064

$31,686

Each additional class

19(1)(b)

$1,783

$1,819

Sterile dosage forms

19(1)(c)

$8,883

$9,061

Packaging/Labelling of Drugs — Schedule 3

Basic fee

20(1), 20(3)(a), 28(1)(b), 28(2)(b)

$11,869

$12,107

Each additional category

20(1)(a)

$2,966

$3,026

Dosage form classes:

   

2 classes

20(1)(b)

$5,920

$6,039

3 or more classes

20(1)(b)

$8,883

$9,061

Importation and Distribution of Drugs — Schedule 4

Basic fee

21(a), 22, 28(1)(c) and (d), 28(2)(c) and (d)

$7,402

$7,551

Each additional category

21(a)(i), 22(a)

$1,853

$1,891

Dosage form classes:

   

2 classes

21(a)(ii), 22(b)

$3,703

$3,778

3 or more classes

21(a)(ii), 22(b)

$7,402

$7,551

Each fabricator

21(b)(i)

$1,783

$1,819

Each additional dosage form class for each fabricator

21(b)(ii)

$899

$917

Distribution or Wholesaling

Distribution or wholesaling fee

23

$4,449

$4,538

Testing

Testing fee

24

$2,966

$3,026

Drug Analysis — Schedule 5

Vaccines (1)

25

$29,582

$30,174

Drugs, not included in items 1, 6 and 9 of this Schedule, that are listed in Schedule D to the Food and Drugs Act

25

$11,836

$12,073

Drugs for human use that are listed in Schedule F to the Food and Drug Regulations or that are controlled drugs or narcotics

25

$8,883

$9,061

Drugs for human use, not included in any other item, for which a drug identification number has been assigned

25

$4,449

$4,538

Radiopharmaceuticals

25

$0

$0

Whole blood and its components (6)

25

$0

$0

Hemodialysis products

25

$0

$0

Drugs that are labelled as disinfectants, including those listed in paragraph 9(f) of this Schedule, but excluding other drugs labelled as disinfectants of medical devices

25

$0

$0

Drugs that meet the requirements of a class monograph having one of the following titles (9):

$0

$0

Acne Therapies

25

$0

$0

Antidandruff Products

25

$0

$0

Antiperspirants

25

$0

$0

Antiseptic Skin Cleaners

25

$0

$0

Athlete’s Foot Treatments

25

$0

$0

Contact Lens Disinfectants 9(f)

25

$0

$0

Fluoride-Containing Anti-Caries Products

25

$0

$0

Medicated Skin Care Products

25

$0

$0

Sunburn Protectants

25

$0

$0

Throat Lozenges

25

$0

$0

Fees for the Examination of Dealer’s Licence Applications

Dealer’s Licence

Dealer’s licence

31(1)

$5,184

$5,288

Fees for Right to Sell Drugs

Annual fee

35(1)

$1,176

$1,200

PART 3 — MEDICAL DEVICE FEES

Fees for the Examination of Medical Device Licence Applications

Class II Medical Devices

Class II — Licence application

39(1)

$405

$414

Class III Medical Devices — Schedule 6

Licence application

40(1)(a), 41(a)

$5,805

$5,922

Licence application for a near patient in vitro diagnostic devices

40(1)(a), 41(a)

$9,881

$10,079

Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing

40(1)(a), 41(a)

$1,462

$1,492

Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations

40(1)(a), 41(a)

$5,437

$5,546

Class IV Medical Devices — Schedule 7

Licence application

40(1)(b), 41(b)

$13,500

$13,770

Licence application for devices that contain human or animal tissue

40(1)(b), 41(b)

$12,594

$12,846

Licence application for near patient in vitro diagnostic device

40(1)(b), 41(b)

$23,012

$23,473

Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing

40(1)(b), 41(b)

$1,462

$1,492

Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations

40(1)(b), 41(b)

$6,195

$6,319

Remission

Remission processing fee

44(1)(a)(iii)

$63

$65

Fee for Right to Sell Licensed Class II, III or IV Medical Devices

Fee (if annual gross revenue medical device sales is less than $20,000)

48(1)(a)

$63

$65

Fee (in any other case)

48(1)(b)

$383

$391

Establishment Licence Fees

Medical devices establishment licence

51(1)

$8,272

$8,438

DEPARTMENT OF HEALTH

FINANCIAL ADMINISTRATION ACT

Notice of annual increase of Health Canada’s veterinary drug fees

Notice is hereby given, under section 17.1 of the Service Fees Act (a fee is adjusted in each fiscal year, on the anniversary of a date that is selected by the responsible authority with respect to the fee before the first adjustment, by the percentage change over 12 months in the April All-items Consumer Price Index for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year), that every fee outlined in the Veterinary Drug Evaluation Fees Regulations, the Establishment Licensing Fees (Veterinary Drugs) Regulations, the Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations, and the Authority to Sell Veterinary Drugs Fees Regulations is to be increased by 2.2%. Health Canada has chosen April 1 as the anniversary date.

The current fees and the fees updated as of April 1, 2019, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or hc.cro-brc.sc@canada.ca (email).

Fee Category

Fees as of April 1, 2018

Fees as of April 1, 2019

Veterinary Drug Evaluation Fees

Item

New drug submission

1

Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species. (In the case of an antiparasitic drug, several indications in one food animal species).

$15,980.00

$16,331.56

2

Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species.

$9,680.00

$9,892.96

3

Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration, dosage form and two indications in one animal species.

$23,240.00

$23,751.28

4

Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species.

$31,470.00

$32,162.34

5

Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration.

$2,900.00

$2,963.80

6

Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength.

$480.00

$490.56

7

For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species.

$21,790.00

$22,269.38

8

For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species.

$29,050.00

$29,689.10

9

For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration.

$2,900.00

$2,963.80

10

For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species.

$14,520.00

$14,839.44

11

Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug.

$4,840.00

$4,946.48

12

Chemistry and manufacturing data to support one strength of a single dosage form.

$4,840.00

$4,946.48

13

Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as item 12.

$2,420.00

$2,473.24

14

Documentation to support a change of manufacturer.

$250.00

$255.50

Supplement to a new drug submission

1

Efficacy data to support an additional indication in one animal species.

$12,590.00

$12,866.98

2

Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species.

$9,680.00

$9,892.96

3

Efficacy and safety data (in the intended species) to support an indication in another animal species.

$15,980.00

$16,331.56

4

Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species.

$23,240.00

$23,751.28

5

Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species.

$31,470.00

$32,162.34

6

Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species.

$7,740.00

$7,910.28

7

Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration.

$2,900.00

$2,963.80

8

Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength.

$480.00

$490.56

9

For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species.

$2,900.00

$2,963.80

10

For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species.

$14,520.00

$14,839.44

11

For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period.

$7,260.00

$7,419.72

12

For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required.

$5,810.00

$5,937.82

13

Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process.

$4,840.00

$4,946.48

14

Chemistry and manufacturing data to support a change in formulation or dosage form.

$2,420.00

$2,473.24

15

Chemistry and manufacturing data to support a change in packaging or in the sterilization process.

$1,930.00

$1,972.46

16

Chemistry and manufacturing data to support an extension of the expiry dating.

$1,450.00

$1,481.90

17

Chemistry and manufacturing data to support the concurrent use of two drugs.

$1,450.00

$1,481.90

18

Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage forms.

$480.00

$490.56

19

Documentation to support a change to the name of a manufacturer or the brand name of a drug.

$250.00

$255.50

Abbreviated new drug submission and supplement to an abbreviated new drug submission

1

Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form.

$2,900.00

$2,963.80

2

For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product.

$2,900.00

$2,963.80

3

Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug.

$4,840.00

$4,946.48

4

Chemistry and manufacturing data to support a single dosage form.

$4,840.00

$4,946.48

5

Documentation to support

  • (a) a change of manufacturer, in the case of an abbreviated new drug submission; or
  • (b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission.

$250.00

$255.50

Drug identification number application

1

Information, other than that referred to in item 2, to support an application for a number, including the submission of labelling material for a second review, if required.

$720.00

$735.84

2

Published references or other data.

$500.00

$511.00

3

Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug.

$250.00

$255.50

Preclinical new drug submission

1

Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species.

$4,840.00

$4,946.48

2

Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated.

$3,870.00

$3,955.14

3

For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species.

$14,520.00

$14,839.44

4

For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species.

$21,790.00

$22,269.38

5

For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species.

$29,050.00

$29,689.10

6

For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species.

$7,260.00

$7,419.72

7

Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient.

$4,840.00

$4,946.48

8

Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient.

$2,420.00

$2,473.24

Notifiable change or protocol review

1

Information and material to support an application for notifiable change.

$1,300.00

$1,300.00

2

Request for review of scientific information outside of a regular drug submission (i.e. review of a proposed trial protocol).

$1,300.00

$1,300.00

Experimental studies certificate

1

Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal.

$960.00

$981.12

2

Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal.

$480.00

$490.56

3

Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal.

$2,900.00

$2,963.80

4

Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal.

$480.00

$490.56

Emergency drug sale

1

Information and material to support the sale of a drug to be used in the emergency treatment of a non-food-producing animal.

$50.00

$51.10

2

Information and material to support the sale of a drug to be used in the emergency treatment of a food-producing animal.

$100.00

$102.20

Veterinary Drug Establishment Licence Fees

Good Manufacturing Practices Component

A. Fabrication

Basic fee

$6,000.00

$6,132.00

Each additional category

$1,500.00

$1,533.00

Dosage form classes:

2 classes

$3,000.00

$3,066.00

3 classes

$6,000.00

$6,132.00

4 classes

$7,500.00

$7,665.00

5 classes

$9,000.00

$9,198.00

6 classes

$10,500.00

$10,731.00

Each additional class

$600.00

$613.20

Sterile dosage forms

$3,000.00

$3,066.00

B. Packaging/Labelling

Basic fee

$4,000.00

$4,088.00

Each additional category

$1,000.00

$1,022.00

Dosage form classes:

2 classes

$2,000.00

$2,044.00

3 or more classes

$3,000.00

$3,066.00

C. Importation/Distribution

Basic fee

$2,500.00

$2,555.00

Each additional category

$625.00

$638.75

Dosage form classes:

2 classes

$1,250.00

$1,277.50

3 or more classes

$2,500.00

$2,555.00

Each fabricator

$600.00

$613.20

Each additional dosage form class for each fabricator

$300.00

$306.60

D. Distribution and Wholesaling

Distribution and wholesaling fee

$1,500.00

$1,533.00

E. Testing

Testing fee

$1,000.00

$1,022.00

Drug Analysis Component

Drug identification numbers for veterinary use

$250.00

$255.50

Dealer’s Licence

Dealer’s licence

$1,750.00

$1,788.50

Fees For Right To Sell Veterinary Drugs

Annual fee

$250.00

$255.50

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Filing of claims for exemption

Pursuant to paragraph 12(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the filing of the claims for exemption listed below.

In accordance with subsection 12(2) of the Hazardous Materials Information Review Act, affected parties, as defined, may make written representations to the screening officer with respect to the claim for exemption and the safety data sheet (SDS) or label to which it relates. Written representations must cite the appropriate registry number, state the reasons and evidence upon which the representations are based and be delivered within 30 days of the date of the publication of this notice in the Canada Gazette, Part I, to the screening officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 8th Floor (4908-B), Ottawa, Ontario K1A 0K9.

Véronique Lalonde
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended, and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015.

The claims listed below seek an exemption from the disclosure of supplier confidential business information in respect of a hazardous product; such disclosure would otherwise be required under the provisions of the relevant legislation.

Claimant

Product Identifier

Subject of the Claim for Exemption

Registry Number

Xypex Chemicals Corporation

Xypex Concentrate

C. of two ingredients C.i. and C. of three ingredients

12366

Xypex Chemicals Corporation

Xypex Modified

C. of two ingredients C.i. and C. of three ingredients

12367

Xypex Chemicals Corporation

Xypex Patch’n Plug

C. of two ingredients C.i. and C. of three ingredients

12368

BASF Canada Inc.

Inoterra DWE

C.i. and C. of one ingredient C.i. of one ingredient

12369

GREENSOLV Inc. (Produits Environnementaux Greensolv inc.)

GREENSOLV 294WL

C.i. and C. of four ingredients

12370

Fluid Energy Group Ltd.

Enviro-Syn® HCR-7000FRAC

C.i. and C. of one ingredient

03319747

Fluid Energy Group Ltd.

Enviro-Syn® HCR-7000FRAC-WL

C.i. and C. of one ingredient

03319912

Power Service Products

DIESEL FUEL SUPPLEMENT + CETANE BOOST 1:400 Treatment Ratio

C.i. of eight ingredients

03320727

Power Service Products

DIESEL FUEL SUPPLEMENT + CETANE BOOST 1:1,000 Treatment Ratio

C.i. of thirteen ingredients

03320726

Power Service Products

DIESEL FUEL SUPPLEMENT + CETANE BOOST 1:1,500 Treatment Ratio

C.i. of fourteen ingredients

03320725

Power Service Products

DIESEL KLEEN + CETANE BOOST 1:400 Treatment Ratio

C.i. of nine ingredients

03320723

Power Service Products

DIESEL KLEEN + CETANE BOOST 1:1,000 Treatment Ratio

C.i. of nine ingredients

03320722

Power Service Products

DIESEL KLEEN + CETANE BOOST 1:1,500 Treatment Ratio

C.i. of nine ingredients

03320720

ROMIX, Inc.

BACK-SET MOLECULAR CEMENT DISSOLVER

C.i. and C. of one ingredient

03320950

Imperial Oil Limited

VALVE GREASE NO.1

C.i. and C. of one ingredient

03320737

Multi-Chem Production Chemicals Co. (C/O Multi-Chem Group LLC)

RockOn™ MX 5-3447

C.i. of three ingredients

03319910

BASF Canada Inc.

Irgacor L 844

C.i. and C. of one ingredient

03319808

Fluid Energy Group Ltd.

Enviro-Syn® HCR-2000CEF

C.i. and C. of one ingredient

03319909

BASF Canada Inc.

Irgalube 875

C.i. of one ingredient

03319809

Ecolab Co.

Ultrasil 09

C.i. of one ingredient

03320190

Canadian Energy Services LP

ENERSCAV C

C.i. and C. of one ingredient

03321522

Integrity Bio-Chem

CleanSurf™ 55

C.i. and C. of one ingredient

03320815

Covestro LLC

DESMODUR WP 260

C.i. and C. of one ingredient C. of one ingredient

03320730

Flotek Chemistry

EZ Mulse

C.i. and C. of one ingredient

03320862

Nalco Canada ULC

PARA01532A

C.i. and C. of one ingredient

03320238

Nalco Canada ULC

MNE6200

C.i. and C. of five ingredients

03321150

Nalco Canada ULC

PARA01570A

C.i. and C. of one ingredient

03321198

Nalco Canada ULC

DURASOFT™ 64870

C.i. of two ingredients

03321047

SUEZ Water Technologies & Solutions Canada

SPEC-AID 8Q107ULS

C.i. and C. of one ingredient

03321005

SUEZ Water Technologies & Solutions Canada

PROSWEET S1791

C.i. and C. of one ingredient

03321485

SUEZ Water Technologies & Solutions Canada

PETROFLO 20Y99

C.i. and C. of two ingredients

03321004

SUEZ Water Technologies & Solutions Canada

PHILMPLUS 5K35

C.i. and C. of three ingredients

03321486

SUEZ Water Technologies & Solutions Canada

STYREX40

C.i. and C. of one ingredient

03321003

SUEZ Water Technologies & Solutions Canada

STYREX50

C.i. and C. of one ingredient

03321000

SUEZ Water Technologies & Solutions Canada

PETROFLO 20Y98

C.i. and C. of two ingredients

03320998

Covestro LLC

SOFTCEL POLYOL VE-1500

C.i. and C. of one ingredient

03321185

Covestro LLC

SOFTCEL POLYOL VE-1800

C.i. and C. of one ingredient

03321184

Nalco Canada ULC

ENTERFAST™ EC9008B

C.i. of one ingredient

03321066

WD-40 Company (Canada) Ltd.

3-IN-ONE® RVcare Rubber Seal Conditioner

C.i. of one ingredient

03321767

Nalco Canada ULC

NALCO® EC1436A

C.i. of two ingredients

03321073

Nalco Canada ULC

Clar10650A

C.i. of one ingredient

03321187

Evonik Canada Inc.

Protectosil® CHEM-TRETE® PB 100

C.i. and C. of two ingredients and one toxicological study

03321312

Integrity Bio-Chem

CleanSurf™ 55W

C.i. of one ingredient

03321656

SUEZ Water Technologies & Solutions Canada

GENGARD GN8020

C.i. and C. of one ingredient

03321738

SUEZ Water Technologies & Solutions Canada

GENGARD GN8220

C.i. and C. of one ingredient

03321739

SUEZ Water Technologies & Solutions Canada

GENGARD GN8221

C.i. and C. of one ingredient

03321740

SUEZ Water Technologies & Solutions Canada

GENGARD GN8222

C.i. and C. of one ingredient

03321741

SUEZ Water Technologies & Solutions Canada

GENGARD GN8224

C.i. and C. of one ingredient

03321742

SUEZ Water Technologies & Solutions Canada

GENGARD GN8225

C.i. and C. of one ingredient

03321744

SUEZ Water Technologies & Solutions Canada

GENGARD GN8240

C.i. and C. of one ingredient

03321745

SUEZ Water Technologies & Solutions Canada

GENGARD GN8021

C.i. and C. of one ingredient

03321746

Note: C.i. = chemical identity and C. = concentration

DEPARTMENT OF HEALTH

PATENT ACT

Notice of annual increase of fees pursuant to the Certificate of Supplementary Protection Regulations

Notice is hereby given that, in keeping with subsection 9(1) of the Certificate of Supplementary Protection Regulations, the fee will increase by the annual 2% amount, rounded up to the nearest dollar.

The current fee and the fee updated as of April 1, 2019, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or hc.cro-brc.sc@canada.ca (email).

 

Subsection in Certificate of Supplementary Protection Regulations

Fee as of April 1, 2018

Fee as of April 1, 2019

Certificate of Supplementary Protection

9(1)

$9,192

$9,376

DEPARTMENT OF TRANSPORT

CANADA TRANSPORTATION ACT

Levy on shipments of crude oil by rail

Pursuant to subsection 155.4(4) footnote * of the Canada Transportation Act (the Act), the amount of the levy in respect of payments into the Fund for Railway Accidents Involving Designated Goods required by subsection 155.7(1)footnote * of the Act is $1.76 per tonne during the year commencing April 1, 2019.

March 4, 2019

Marc Garneau, P.C., M.P.
Minister of Transport

INNOVATION, SCIENCE AND ECONOMIC DEVELOPMENT CANADA

RADIOCOMMUNICATION ACT

Notice No. SMSE-003-19 — Release of Decision on the Technical and Policy Framework for White Space Devices and Decision on the Technical, Policy and Licensing Framework for Wireless Microphones

Notice is hereby given that Innovation, Science and Economic Development Canada (ISED) has published the following decisions:

These decisions respectively address spectrum utilization by white space devices in the very high frequency and ultra-high frequency ranges, and wireless microphones in the ultra-high frequency and super high frequency ranges.

Obtaining copies

Copies of this notice and of documents referred to herein are available electronically on the Spectrum Management and Telecommunications website.

Official versions of notices can be viewed on the Canada Gazette website.

March 2019

Martin Proulx
Director General
Engineering, Planning and Standards Branch

OFFICE OF THE SUPERINTENDENT OF FINANCIAL INSTITUTIONS

BANK ACT

Silicon Valley Bank — Order to commence and carry on business in Canada

Notice is hereby given of the issuance, pursuant to subsection 534(1) of the Bank Act, of an order authorizing a foreign bank, Silicon Valley Bank, to commence and carry on business in Canada, effective February 27, 2019. The foreign bank is permitted to carry on business in Canada under the name, in English, Silicon Valley Bank and, in French, Banque Silicon Valley.

March 12, 2019

Jeremy Rudin
Superintendent of Financial Institutions

PRIVY COUNCIL OFFICE

Appointment opportunities

We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. The Government of Canada has implemented an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous peoples and minority groups are properly represented in positions of leadership. We continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.

We are equally committed to providing a healthy workplace that supports one’s dignity, self-esteem and the ability to work to one’s full potential. With this in mind, all appointees will be expected to take steps to promote and maintain a healthy, respectful and harassment-free work environment.

The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.

Current opportunities

The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council Appointments website.

Position

Organization

Closing date

Chief Administrator

Administrative Tribunals Support Service of Canada

 

Chairperson

Asia-Pacific Foundation of Canada

 

Chairperson

Canada Development Investment Corporation

 

Chairperson

Canada Foundation for Sustainable Development Technology

 

Chairperson and Vice-Chairperson

Canada Industrial Relations Board

 

Chairperson

Canada Lands Company Limited

 

President and Chief Executive Officer

Canada Lands Company Limited

 

Chairperson (joint federal Governor in Council and provincial Lieutenant Governor appointment)

Canada–Newfoundland and Labrador Offshore Petroleum Board

 

Chairperson

Canada Science and Technology Museum

 

Vice-Chairperson

Canada Science and Technology Museum

 

Board Member (Anticipatory)

Canadian Accessibility Standards Development Organization

 

Chairperson (Anticipatory)

Canadian Accessibility Standards Development Organization

 

Chief Executive Officer (Anticipatory)

Canadian Accessibility Standards Development Organization

 

Vice-Chairperson (Anticipatory)

Canadian Accessibility Standards Development Organization

 

President and Chief Executive Officer

Canadian Commercial Corporation

 

Chairperson

Canadian Dairy Commission

 

Chairperson, Vice-Chairperson and Director

Canadian Energy Regulator

 

Chief Executive Officer (Anticipatory)

Canadian Energy Regulator

 

Lead Commissioner, Deputy Lead Commissioner and Commissioner

Canadian Energy Regulator

 

Pay Equity Commissioner

Canadian Human Rights Commission

 

Chairperson

Canadian Institutes of Health Research

 

Vice-Chairperson

Canadian Museum of Nature

 

Permanent Member

Canadian Nuclear Safety Commission

 

Regional Member (Quebec)

Canadian Radio-television and Telecommunications Commission

 

Chairperson and Member

Canadian Statistics Advisory Council

 

President (Chief Executive Officer)

Canadian Tourism Commission

 

President and Chief Executive Officer

Defense Construction (1951) Limited

 

Chairperson

Farm Credit Canada

 

President and Chief Executive Officer

Farm Credit Canada

 

Vice-Chairperson

Farm Products Council of Canada

 

Chairperson

The Federal Bridge Corporation Limited

 

Commissioner

Financial Consumer Agency of Canada

 

Chairperson

First Nations Financial Management Board

 

Chief Commissioner

First Nations Tax Commission

 

Deputy Chief Commissioner

First Nations Tax Commission

 

Director

Freshwater Fish Marketing Corporation

 

Director (Federal)

Hamilton Port Authority

 

Sergeant-at-Arms and Corporate Security Office

House of Commons

 

Member

International Authority

 

Commissioner and Chairperson

International Joint Commission

 

Member (appointment to roster)

International Trade and International Investment Dispute Settlement Bodies

 

Vice-Chairperson

Invest in Canada Hub

 

Chief Executive Officer

The Jacques Cartier and Champlain Bridges Incorporated

 

Librarian and Archivist of Canada

Library and Archives of Canada

 

President and Chief Executive Officer

Marine Atlantic Inc.

 

Vice-Chairperson

National Arts Centre Corporation

 

Member

National Capital Commission

 

Government Film Commissioner

National Film Board

 

Chairperson

National Research Council of Canada

 

President

Natural Sciences and Engineering Research Council of Canada

 

Canadian Ombudsperson

Office of the Canadian Ombudsperson for Responsible Enterprise

 

Chief Accessibility Officer (Anticipatory)

Office of the Chief Accessibility Officer

 

Ombudsperson

Office of the Ombudsperson for National Defence and Canadian Forces

 

Director (Federal)

Oshawa Port Authority

 

Chairperson

Pacific Pilotage Authority

 

Chief Executive Officer

Parks Canada

 

Vice-Chairperson and Member

Patented Medicine Prices Review Board

 

Member

Payment in Lieu of Taxes Dispute Advisory Panel

 

Commissioner

Public Service Commission

 

Member and Alternate Member

Renewable Resources Board (Gwich’in)

 

Member and Alternate Member

Renewable Resources Board (Sahtu)

 

Chairperson and Vice-Chairperson

Royal Canadian Mounted Police External Review Committee

 

Principal

Royal Military College of Canada

 

Vice-Chairperson (all streams)

Social Security Tribunal of Canada

 

Chairperson

Telefilm Canada

 

Member (Marine and Medical)

Transportation Appeal Tribunal of Canada

 

President and Chief Executive Officer

VIA Rail Canada Inc.

 

BANK OF CANADA

Statement of financial position as at February 28, 2019

(Millions of dollars) Unaudited

ASSETS

Cash and foreign deposits

 

17.8

Loans and receivables

Securities purchased under resale agreements

9,709.8

 

Advances

 

Other receivables

4.0

 
   

9,713.8

Investments

Treasury bills of Canada

23,828.1

 

Canada Mortgage Bonds

252.3

 

Government of Canada bonds

79,490.0

 

Other investments

431.5

 
   

104,001.9

Capital assets    

Property and equipment

599.8

 

Intangible assets

46.4

 

Right-of-use leased assets

53.7

 
   

699,9

Other assets

 

187.7

 

114,621.1


LIABILITIES AND EQUITY

Bank notes in circulation

 

86,328.4

Deposits

Government of Canada

23,730.3

 

Members of Payments Canada

250.4

 

Other deposits

3,018.8

 
   

26,999.5

Securities sold under repurchase agreements

 

Other liabilities

 

769.7

   

114,097.6

Equity

Share capital

5.0

 

Statutory and special reserves

125.0

 

Investment revaluation reservefootnote 1*

393.5

 
   

523.5

114,621.1

I declare that the foregoing statement is correct according to the books of the Bank.

Ottawa, March 15, 2019

Carmen Vierula
Chief Financial Officer and Chief Accountant

I declare that the foregoing statement is to the best of my knowledge and belief correct, and shows truly and clearly the financial position of the Bank, as required by section 29 of the Bank of Canada Act.

Ottawa, March 15, 2019

Stephen S. Poloz
Governor